Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis

PURPOSE: Following the publication of 5-year agalsidase alfa enzyme replacement therapy (ERT) outcomes data from the Fabry Outcome Survey (FOS), 10-year data were analyzed. PATIENTS AND METHODS: FOS (ClinicalTrials.gov identifier: NCT03289065) data (April 2001 to August 2018) were retrospectively an...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Drug Des Devel Ther
Prif Awduron: Ramaswami, Uma, Beck, Michael, Hughes, Derralynn, Kampmann, Christoph, Botha, Jaco, Pintos-Morell, Guillem, West, Michael L, Niu, Dau-Ming, Nicholls, Kathy, Giugliani, Roberto
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove 2019
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6819672/
https://ncbi.nlm.nih.gov/pubmed/31749608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S207856
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg